Related Experiment Video
Updated: Jun 10, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization
Xin Guo1, Meng-Jun Tao2, XinCan Ji1
1School of Public Health, Wannan Medical College, No. 22, Wenchang West Road, Yijiang District, Wuhu, Anhui, China.
Abstract:
Psoriasis is a chronic inflammatory skin disorder with multiple causes, including genetic and environmental factors. Despite advances in treatment, there remains a need to identify novel therapeutic targets. A Mendelian randomization (MR) analysis was conducted to identify therapeutic targets for psoriasis. Data on cis-expression quantitative trait loci were obtained from the eQTLGen Consortium (n = 31,684). Summary statistics for psoriasis (outcome) were sourced from the GWAS Catalog with a sample size of 484,598, including 5,427 cases and 479,171 controls. Colocalization analysis was used to assess whether psoriasis risk and gene expression were driven by shared single nucleotide polymorphisms. Drug prediction and molecular docking were utilized to validate the pharmacological value of the drug targets. The MR analysis found that 81 drug targets were significantly associated, and two (TYK2 and PRSS36) were supported by colocalization analysis (PP.H4 > 0.80). Phenome-wide association studies did not show any associations with other traits at the gene level. Biologically, these genes were closely related to immune function. Molecular docking revealed strong binding with drugs and proteins, as supported by available structural data. This study validated TYK2 as a drug target for psoriasis, in line with its existing clinical use, including the development of decucravacitinib. PRSS36 is a potential novel target requiring further investigation.
Insights
This study identified potential new drug targets for psoriasis using Mendelian randomization. TYK2 was validated as a target, and PRSS36 emerged as a promising novel candidate for psoriasis treatment.
Area of Science:
- Genetics
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition with complex genetic and environmental origins.
- Current treatments for psoriasis are advancing, yet novel therapeutic targets are still needed.
- Identifying new drug targets can improve patient outcomes for this widespread disorder.
Purpose of the Study:
- To utilize Mendelian randomization to uncover novel therapeutic targets for psoriasis.
- To validate potential drug targets through colocalization and molecular docking analyses.
- To explore the genetic underpinnings of psoriasis for improved therapeutic strategies.
Main Methods:
- Mendelian randomization analysis using cis-expression quantitative trait loci data and psoriasis genome-wide association study summary statistics.
- Colocalization analysis to assess shared genetic drivers of psoriasis risk and gene expression.
- Drug prediction and molecular docking to evaluate the pharmacological potential of identified targets.
Main Results:
- Mendelian randomization identified 81 significantly associated drug targets.
- Colocalization analysis supported TYK2 and PRSS36 as key targets.
- TYK2 is confirmed as a viable target, aligning with existing therapies; PRSS36 is a novel candidate for further research.
Conclusions:
- TYK2 is a validated drug target for psoriasis, consistent with current clinical applications.
- PRSS36 represents a novel potential therapeutic target for psoriasis requiring additional investigation.
- This research provides a genetic basis for developing new psoriasis treatments.
